FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
|Slideshows|January 4, 2017
Neuro News Roundup: Parkinson & Cognitive Function
Author(s)Mark L. Fuerst
Orthostatic hypotension’s effect on cognition in Parkinson disease, testing patients with epilepsy who can drive safely, and carotid web are covered.
Advertisement
Three new neurology studies show that orthostatic hypotension appears to cause cognition disturbances in Parkinson disease; video testing with electroencephalograph monitoring may determine which epilepsy patients can drive safely, and carotid web may be an underappreciated risk factor for stroke.
Advertisement
Related to this article
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.
Seven investigational cerebral palsy therapies—from baby-tooth stem cells to cannabinoids and botulinum toxin—show mixed early results, highlighting key clinical trial milestones ahead.
Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.
Exploratory extracellular vesicle biomarkers suggested KP405, a brain-penetrant GLP-1/GIP agonist, engaged insulin signaling and neuroinflammation pathways in a small phase 1 study.
Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease
2
12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease
3
Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses
4
Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis
5